Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal.

The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx for $28 each was expected have a value of $1.9 billion net of estimated cash required.